Australia TGA Medical Device Registration: The Complete Guide
How to register medical devices with Australia's TGA — classification, ARTG inclusion, sponsor requirements, MDSAP, fees, and practical guidance for the Australian market.
Why the Australian Market Matters
Australia is one of the most attractive medical device markets in the Asia-Pacific region. With a population of over 26 million, a well-funded universal healthcare system (Medicare), high per-capita health expenditure, and strong hospital infrastructure, it represents a substantial commercial opportunity — particularly for manufacturers of high-technology devices, diagnostics, and digital health solutions.
But the Australian market is not a simple checkbox. The Therapeutic Goods Administration (TGA) operates a rigorous, risk-proportionate regulatory framework that has its own classification system, its own conformity assessment requirements, and its own post-market obligations. While Australia recognizes international standards and accepts certain overseas certifications, it is not a rubber-stamp jurisdiction. Manufacturers who assume they can leverage EU CE marking or FDA clearance without understanding TGA-specific requirements will encounter delays, additional information requests, and potential rejections.
This guide covers every aspect of TGA medical device registration: the regulatory framework, device classification, application pathways, sponsor requirements, conformity assessment, MDSAP acceptance, clinical evidence, fees, IVD-specific requirements, post-market obligations, the Trans-Tasman arrangement with New Zealand, recent reforms, and practical guidance for foreign manufacturers entering the Australian market.
The Regulatory Framework
The Therapeutic Goods Administration (TGA)
The TGA is Australia's regulatory authority for therapeutic goods, including medicines, medical devices, biologicals, and blood products. It sits within the Australian Government Department of Health and Aged Care and is responsible for pre-market assessment, post-market monitoring, and enforcement of the Therapeutic Goods Act 1989 (the Act).
The TGA's regulatory framework for medical devices is primarily governed by:
- Therapeutic Goods Act 1989 — the primary legislation establishing the regulatory scheme for therapeutic goods in Australia
- Therapeutic Goods (Medical Devices) Regulations 2002 — the detailed regulations governing medical device classification, conformity assessment, essential principles, and registration
- Therapeutic Goods Regulations 1990 — additional regulations including advertising, labeling, and certain procedural requirements
- Various TGA orders and guidance documents — covering specific device types, clinical evidence requirements, and procedural matters
The Australian Register of Therapeutic Goods (ARTG)
The ARTG is the central register of all therapeutic goods legally available for supply in Australia. Every medical device — with limited exceptions — must be included in the ARTG before it can be imported, exported, or supplied in Australia.
The ARTG is publicly searchable at the TGA website and contains information about registered and listed devices, including the product name, ARTG number, device classification, sponsor details, and conditions of inclusion.
The distinction between "listed" and "registered" devices is important:
| ARTG Status | ARTG Number Prefix | Applicable Device Classes | Level of TGA Assessment |
|---|---|---|---|
| Listed | AUST L | Class I (non-sterile, non-measuring), Class I (sterile), Class I (measuring) | Lower-risk devices — self-assessed by the sponsor against legislative requirements. TGA does not review before listing but may audit post-market. |
| Registered | AUST R | Class IIa, Class IIb, Class III, AIMD, and all IVDs requiring conformity assessment | Higher-risk devices — TGA reviews the application, conformity assessment evidence, and supporting documentation before granting inclusion. |
Each ARTG entry is assigned a unique ARTG number that must appear on the device label. Listed devices receive an AUST L number; registered devices receive an AUST R number. The ARTG is publicly searchable on the TGA website (tga.gov.au), and anyone — including competitors, healthcare providers, and patients — can look up a device's ARTG number to verify its registration status, sponsor details, device classification, and conditions of inclusion.
Key distinction: "Listed" does not mean unregulated. Listed devices must still comply with all applicable Essential Principles, labeling requirements, and post-market obligations. The TGA conducts risk-based compliance audits of listed devices, and it can suspend or cancel listings if non-compliance is found. The lower pre-market scrutiny is offset by the expectation that the sponsor has thoroughly self-assessed compliance.
Device Classification
Australia's device classification system is closely aligned with the Global Harmonization Task Force (GHTF — now IMDRF) framework and shares significant similarities with the EU system. Devices are classified based on the level of risk they pose to patients and users, taking into account factors such as invasiveness, duration of contact, active versus non-active, and intended purpose.
Classification Overview
| Class | Risk Level | Examples | ARTG Status |
|---|---|---|---|
| Class I | Lowest | Non-invasive wound dressings, tongue depressors, reusable surgical instruments, wheelchairs, examination gloves (non-sterile) | Listed |
| Class I (sterile) | Low | Sterile surgical gloves, sterile wound dressings, sterile syringes (without needles) | Listed (but conformity assessment for sterilization aspects required) |
| Class I (measuring) | Low | Non-invasive blood pressure monitors, clinical thermometers | Listed (but conformity assessment for measuring aspects required) |
| Class IIa | Low–moderate | Hearing aids, powered surgical instruments, diagnostic ultrasound equipment, contact lenses, surgical sutures | Registered |
| Class IIb | Moderate–high | Ventilators, dialysis machines, orthopedic implants (plates, screws), infusion pumps, condoms, lung ventilators | Registered |
| Class III | Highest | Heart valves, spinal disc implants, total joint replacements, drug-eluting stents, breast implants, absorbable sutures | Registered |
| AIMD | Highest (active implant) | Pacemakers, implantable defibrillators, cochlear implants, implantable neurostimulators | Registered |
Classification Rules
The TGA's classification rules are set out in Schedule 2 of the Therapeutic Goods (Medical Devices) Regulations 2002. There are 19 classification rules organized by device type:
| Rule Group | Rules | Covers |
|---|---|---|
| Non-invasive devices | Rules 1–4 | Devices that do not penetrate the body or contact only intact skin |
| Invasive devices | Rules 5–8 | Body orifice devices, surgically invasive devices (transient, short-term, long-term) |
| Active devices | Rules 9–12 | Active therapeutic devices, active diagnostic devices, active devices for administering or exchanging energy or substances |
| Special rules | Rules 13–19 | Devices incorporating medicinal substances, devices used for contraception or prevention of STIs, disinfection/sterilization devices, devices made from animal tissue, blood bags, devices with a measuring function, software as a medical device |
Software as a Medical Device (SaMD)
Australia has adopted the IMDRF framework for classifying software as a medical device. SaMD classification in Australia considers two key factors:
- Significance of the information provided by the SaMD to the healthcare decision or condition
- State of the healthcare situation or condition — whether it is critical, serious, or non-serious
The TGA published specific guidance on SaMD regulation (including the TGA's "Regulation of software as a medical device" guidance document), and software that meets the definition of a medical device must be classified and included in the ARTG.
| Healthcare Situation | Treat or Diagnose | Drive Clinical Management | Inform Clinical Management |
|---|---|---|---|
| Critical | Class III | Class IIb | Class IIa |
| Serious | Class IIb | Class IIa | Class IIa |
| Non-serious | Class IIa | Class IIa | Class I |
Practical tip: Classification in Australia is your responsibility as the sponsor, not the TGA's. The TGA does not issue binding pre-market classification decisions the way the FDA does with product codes. If you misclassify your device and proceed through the wrong pathway, you face potential enforcement action, ARTG cancellation, and supply disruption. When classification is ambiguous — particularly for software, combination products, or devices with novel intended purposes — seek a pre-submission meeting with the TGA or engage an experienced Australian regulatory consultant.
The Australian Sponsor
This is one of the most important concepts in Australian medical device regulation, and one that foreign manufacturers frequently underestimate.
What Is a Sponsor?
Under the Therapeutic Goods Act, a "sponsor" is the person or entity responsible for importing, exporting, manufacturing, or supplying a therapeutic good in Australia. Only a sponsor can apply for ARTG inclusion. The sponsor is the legal entity that bears regulatory responsibility for the device in Australia — they are the TGA's point of contact, they must maintain records, they must handle adverse event reporting, and they are liable for any regulatory non-compliance.
Sponsor Requirements
- Australian presence required. The sponsor must be an individual resident in Australia, or a body corporate incorporated in Australia. A foreign manufacturer cannot be the sponsor unless they have an Australian corporate entity.
- The sponsor need not be the manufacturer. The sponsor can be the manufacturer's Australian subsidiary, an Australian distributor, an Australian authorized representative, or any other entity that meets the residency/incorporation requirement and accepts the regulatory obligations.
- Regulatory responsibilities. The sponsor is responsible for: ARTG application and maintenance, adverse event and incident reporting to the TGA, post-market surveillance, recall management, maintaining technical documentation in Australia, ensuring ongoing compliance with Essential Principles, and paying annual charges.
- Cannot transfer easily. Changing the sponsor for an ARTG entry requires a formal transfer application to the TGA, which incurs fees and administrative effort. The existing sponsor must submit a transfer form, and sponsor transfer requests should be lodged before 30 June to avoid incurring annual charges under the outgoing sponsor's name.
Sponsor Obligations in Detail
The January 2026 TGA guidance update provided further clarity on sponsor obligations, reinforcing the following:
- Importation accountability: The sponsor is responsible for ensuring that all devices they import, export, or supply in Australia are included in the ARTG. The TGA clarified that misunderstanding the sponsor role is not an acceptable defence against non-compliance.
- Documentation access: The sponsor must maintain access to technical documentation, conformity assessment evidence, and clinical evaluation reports at all times. The TGA may request this documentation at any point during the device's lifecycle.
- Health professionals as suppliers: The 2026 guidance elaborated on scenarios where health professionals are considered suppliers of medical devices under Australian law, expanding the obligation to ensure devices used in clinical settings are ARTG-included.
Penalties for Non-Compliance
Non-compliance with Australian TGA medical device regulations carries serious consequences:
- Civil sanctions and infringement notices — the TGA can issue fines and compliance directives
- Criminal prosecution — in the most severe cases, including deliberate supply of unregistered devices
- ARTG suspension or cancellation — the TGA can suspend or cancel ARTG entries for non-compliant devices, immediately removing the device from legal supply in Australia
- Public disclosure — the TGA publishes compliance actions, enforcement outcomes, and recall notices on its website, creating reputational risk for non-compliant sponsors
Options for Foreign Manufacturers
Foreign manufacturers who do not have an Australian subsidiary typically use one of these approaches:
| Approach | Description | Pros | Cons |
|---|---|---|---|
| Australian distributor as sponsor | A local distributor agrees to serve as the ARTG sponsor as part of the distribution agreement | Cost-effective; distributor has market knowledge; leverages existing business relationship | You are dependent on the distributor for regulatory control; if the relationship ends, the ARTG entry belongs to the sponsor, not the manufacturer |
| Establish an Australian subsidiary | Set up an Australian Pty Ltd company that serves as the sponsor | Full control over regulatory submissions, compliance, and ARTG entries; independence from third parties | Requires Australian company registration, local staff (or at minimum a local director), ongoing corporate compliance costs |
| Engage a regulatory agent/authorized representative | A professional regulatory affairs firm acts as or identifies a sponsor on your behalf | Access to regulatory expertise; scalable; no need for own Australian entity | Ongoing service fees; less direct control; varies widely in quality |
Critical warning: If your Australian distributor is the ARTG sponsor and you terminate the distribution agreement, the distributor retains the ARTG entry. Transferring it to a new sponsor or your own entity requires TGA approval, the former sponsor's cooperation, and can take months. Many foreign manufacturers have learned this lesson the hard way. If long-term market access is important to your business, seriously consider establishing your own Australian entity or at minimum negotiating clear ARTG transfer provisions in your distribution agreement.
Application Pathways
The pathway to ARTG inclusion depends on the device classification and the conformity assessment evidence available.
Listing (Class I Devices)
Class I devices follow a streamlined listing process. The sponsor:
- Confirms the device is Class I through classification rules
- Ensures the device complies with all applicable Essential Principles (Schedule 1 of the Regulations)
- Holds (or has access to) conformity assessment evidence as applicable — for sterile or measuring Class I devices, this includes a conformity assessment certificate from a TGA-recognized conformity assessment body
- Submits the listing application through the TGA Business Services (TBS) portal
- Pays the listing fee
Listing is largely self-assessed. The TGA does not conduct a pre-market review of listed devices — the sponsor certifies compliance. However, the TGA can and does conduct post-market audits of listed devices, requesting evidence of Essential Principles compliance at any time.
Registration (Class IIa, IIb, III, AIMD)
Registration requires a substantive application that the TGA reviews before granting ARTG inclusion. The application must include:
- Completed application form — submitted through TGA Business Services
- Conformity assessment evidence — demonstrating that the device has been assessed against the applicable Essential Principles. This can take several forms (see Conformity Assessment Procedures below)
- Australian Declaration of Conformity — the manufacturer's declaration that the device conforms to applicable Essential Principles
- Device description and specifications — intended purpose, technology, materials, design
- Labeling — including Australian-specific requirements (sponsor name and address, ARTG number once assigned, batch/lot identification)
- Clinical evidence — a clinical evaluation demonstrating that the device meets the Essential Principles related to safety and performance
- Instructions for use (IFU) — compliant with Australian requirements
- Risk management documentation — risk management file per ISO 14971
- Application fee
Standard Application
The standard application pathway is the default for registering a medical device in the ARTG. The TGA conducts a full assessment of the conformity assessment evidence, clinical evidence, and device documentation. This pathway is used when:
- The device does not hold a recognized overseas certification that qualifies for the abbreviated pathway
- The manufacturer or sponsor prefers or is required to submit under the standard pathway
- The device is subject to specific TGA requirements that are not covered by an overseas certification
Abbreviated Application (Comparable Overseas Regulator Pathway)
This is the pathway most commonly used by foreign manufacturers who already hold regulatory approvals in comparable overseas jurisdictions. The TGA accepts conformity assessment evidence from certain overseas regulators, reducing the scope of the TGA's own assessment.
The TGA recognizes approvals from these comparable overseas regulators (CORs), as established under the Therapeutic Goods (Overseas Regulators) Determination 2018 and its amendments:
| Regulator | Jurisdiction | Recognized Since | Recognition Scope |
|---|---|---|---|
| European Union (CE marking) | EU/EEA | October 2018 | Devices with valid EU MDD/AIMDD/IVDD or EU MDR/IVDR CE marking. Recognition scope has been updated — see "EU CE Marking Recognition" section below. |
| FDA | United States | October 2018 | 510(k) clearance, De Novo classification, PMA approval. From October 2024, expanded reliance pathways also accept MDSAP Certification + FDA 510(k) clearance for Class III devices. |
| Health Canada | Canada | October 2018 | Medical device licences (Class IV). TGA accepts MDSAP certificate plus Health Canada medical device licence. |
| Japan (MHLW/PMDA) | Japan | October 2018 | Pre-market approval certificates from the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA). TGA accepts MDSAP certificate plus PMDA pre-market approval certificate. |
| Singapore (HSA) | Singapore | September 2022 | Health Sciences Authority product registration. For Class D (highest risk) devices, TGA accepts the HSA form supporting entry in the Singapore Register of Health Products. |
| MDSAP certificate | Multi-jurisdictional | October 2018 | MDSAP certificates covering Australia scope (see MDSAP section below) |
Specific COR Evidence Accepted by Device Class
For Class III medical device applications, the TGA accepts the following specific documentation from each COR:
| Comparable Overseas Regulator | Documents Accepted for Class III Application |
|---|---|
| Health Canada | MDSAP certificate + Medical device licence (Class IV) |
| Japan (MHLW/PMDA) | MDSAP certificate + Pre-market approval certificate |
| EU (MDR) | Annex IX QMS certificate + Annex IX Technical documentation assessment certificate |
| EU (MDD legacy) | Annex II.3 certificate + Annex II.4 design examination certificate |
| US FDA | MDSAP certificate + PMA approval |
| Singapore (HSA) | Form supporting entry in Singapore Register of Health Products (Class D) |
Criteria for COR recognition: The TGA evaluates potential CORs against five criteria: (1) comparability of the regulatory framework, (2) IMDRF membership, (3) lifecycle approach and post-market vigilance, (4) communication and cooperation with overseas regulators, and (5) expertise of the overseas regulator. The TGA has indicated that discussions are underway with the UK MHRA and Brazil ANVISA regarding potential future COR recognition.
Under the abbreviated pathway, the sponsor submits the overseas regulatory approval documentation, and the TGA conducts a reduced assessment, relying in part on the assessment already performed by the comparable overseas regulator. This typically results in faster review times and lower application fees.
Important nuance: The abbreviated pathway is not automatic recognition. The TGA still reviews the application and can request additional information, raise questions about clinical evidence, or require Australian-specific testing. The term "abbreviated" refers to the scope of TGA assessment being reduced, not eliminated. The TGA remains independent in reaching its own decision, even when relying on a COR assessment.
Provisional Registration
The TGA introduced provisional registration as a pathway for medical devices that address a serious or life-threatening condition where there is an unmet clinical need, but where the full body of clinical evidence required for standard registration is not yet available.
Key features of provisional registration:
- Eligibility: The device must address a serious or life-threatening condition, and the sponsor must demonstrate that there are no adequate alternative devices on the ARTG
- Evidence requirements: The sponsor must provide preliminary clinical evidence demonstrating a reasonable likelihood of safety and performance. Full clinical evidence is not required at the time of provisional registration
- Conditions: Provisional registration is granted with conditions — typically requiring the sponsor to generate additional clinical evidence within a specified timeframe and to submit progress reports to the TGA
- Duration: Provisional registration is time-limited, typically granted for up to two years, with the possibility of extension or conversion to full registration upon submission of complete evidence
- Post-market obligations: Enhanced post-market surveillance and reporting requirements apply
Priority Review
The TGA offers a priority review designation for devices that address a serious or life-threatening condition and offer a significant improvement over existing therapies. Priority review does not change the evidentiary requirements — it accelerates the TGA's review timeline. Applications designated for priority review are placed at the front of the assessment queue.
Conformity Assessment Procedures
Conformity assessment is the process by which a manufacturer demonstrates that a medical device meets the applicable Essential Principles. Australia's conformity assessment procedures are set out in the Therapeutic Goods (Medical Devices) Regulations 2002 and closely align with the GHTF/IMDRF framework.
Conformity Assessment Procedure Overview
| Device Class | Applicable Conformity Assessment Procedures | Involvement of Conformity Assessment Body |
|---|---|---|
| Class I (non-sterile, non-measuring) | Manufacturer self-declaration (Full Quality Assurance — Part 1) | None required |
| Class I (sterile) | Full Quality Assurance (Part 1) + Examination of sterile aspects (Part 4) | Required for sterilization aspects only |
| Class I (measuring) | Full Quality Assurance (Part 1) + Examination of measuring aspects (Part 4) | Required for measuring function aspects only |
| Class IIa | Full Quality Assurance (Parts 1 and 3), or Type Examination (Part 2) + Product Verification (Part 5), or Type Examination (Part 2) + Production Quality Assurance (Part 4) | Required |
| Class IIb | Full Quality Assurance (Parts 1 and 3) + Design Examination (Part 6), or Type Examination (Part 2) + Product Verification (Part 5) | Required |
| Class III | Full Quality Assurance (Parts 1 and 3) + Design Examination (Part 6), or Type Examination (Part 2) + Product Verification (Part 5) | Required |
| AIMD | Full Quality Assurance (Parts 1 and 3) + Design Examination (Part 6), or Type Examination (Part 2) + Product Verification (Part 5) | Required |
What Is a Conformity Assessment Body?
In the Australian context, conformity assessment bodies are organizations recognized by the TGA to conduct conformity assessments of medical devices. These include:
- EU Notified Bodies — the TGA accepts conformity assessment certificates issued by EU Notified Bodies for devices that hold CE marking
- MDSAP Auditing Organizations — MDSAP audit reports covering TGA requirements are accepted as conformity assessment evidence
- TGA itself — the TGA can conduct its own conformity assessments, though in practice this is uncommon for devices that have been assessed by recognized overseas bodies
Essential Principles of Safety and Performance
The Essential Principles are Australia's equivalent of the EU's General Safety and Performance Requirements (GSPR) and the FDA's general and special controls. They are set out in Schedule 1 of the Therapeutic Goods (Medical Devices) Regulations 2002 and establish the fundamental safety and performance requirements that every medical device must meet.
The Essential Principles are organized into:
- Part 1: General Principles — the overall risk-benefit balance must be acceptable; devices must be designed and manufactured to be safe and perform as intended; devices must not compromise the clinical condition or safety of patients
- Part 2: Principles about design and construction — chemical, physical, and biological properties; infection and microbial contamination; manufacturing and environmental properties; devices with a measuring function; protection against radiation; software; active devices; mechanical properties
- Part 3: Principles about devices that have specific characteristics — devices with an energy source; self-testing devices; devices with a diagnostic or therapeutic function
- Part 4: Principles about information to be provided with medical devices — labeling; instructions for use
Manufacturers must prepare an Essential Principles checklist — a document mapping each applicable Essential Principle to the standards and evidence used to demonstrate compliance. This is analogous to the GSPR checklist under the EU MDR and is a core document in any ARTG application.
Practical tip: The TGA's Essential Principles are being updated to align more closely with the EU MDR's General Safety and Performance Requirements and IMDRF guidance. As of 2026, the TGA has signaled its intention to further harmonize these requirements. Manufacturers who already maintain a GSPR checklist for EU MDR compliance will find significant overlap with the Australian Essential Principles, though Australia-specific provisions (particularly regarding labeling, electrical safety standards, and country-specific clinical evidence requirements) still need to be addressed separately.
MDSAP and the Australian Market
How MDSAP Works for Australia
The Medical Device Single Audit Program (MDSAP) is one of the most efficient pathways to demonstrate conformity assessment compliance for the Australian market. Australia is one of the five participating regulatory authorities in MDSAP, and the TGA accepts MDSAP audit reports as evidence of conformity assessment compliance.
When an MDSAP audit includes Australia as a participating market, the auditing organization assesses the manufacturer's quality management system against:
- ISO 13485:2016 — as the foundational quality management system standard
- TGA-specific regulatory requirements — layered on top of ISO 13485, covering Australian labeling, adverse event reporting, post-market surveillance, and Essential Principles compliance
An MDSAP certificate covering Australia can be used to support an ARTG application in the same way that an EU Notified Body certificate supports a CE-marked device. For manufacturers already in the MDSAP program, adding Australia as a market scope is often the most cost-effective way to satisfy TGA conformity assessment requirements.
MDSAP vs. Other Conformity Assessment Evidence
| Conformity Assessment Evidence | Accepted by TGA? | Typical Use Case |
|---|---|---|
| MDSAP certificate (Australia scope) | Yes — accepted as conformity assessment evidence | Manufacturers already in MDSAP for other markets (US, Canada, Brazil, Japan) |
| EU Notified Body certificate (CE marking) | Yes — via abbreviated pathway | Manufacturers with existing CE marking seeking Australian market entry |
| FDA clearance/approval | Yes — via abbreviated pathway | US-based manufacturers expanding to Australia |
| Health Canada license | Yes — via abbreviated pathway | Canadian-licensed manufacturers |
| TGA-conducted conformity assessment | Yes — standard pathway | Manufacturers without recognized overseas certification |
Strategic advice for multi-market manufacturers: If you already sell in the US and Canada and hold an MDSAP certificate, adding Australia to your MDSAP scope is almost always the most efficient path to TGA conformity assessment. The incremental audit time for adding TGA requirements to an existing MDSAP audit is modest compared to the cost and complexity of a standalone TGA conformity assessment.
Clinical Evidence Requirements
The TGA requires clinical evidence to demonstrate that a medical device meets the Essential Principles related to safety and performance. This requirement applies to all device classes, though the depth and type of evidence expected varies by risk class.
What Constitutes Clinical Evidence?
The TGA follows the IMDRF definition of clinical evidence, which includes:
- Clinical investigation data — data generated from clinical investigations (clinical trials) conducted with the device
- Clinical experience data — data from commercial use of the device, including post-market surveillance data, adverse event reports, registry data, and published literature
- Clinical literature — published scientific literature relevant to the device type, including clinical data from equivalent devices
Clinical Evidence by Device Class
| Device Class | Clinical Evidence Expectation |
|---|---|
| Class I | Clinical evidence typically based on literature review and clinical experience with equivalent devices. Clinical investigations rarely required. |
| Class IIa | Clinical evaluation based on literature review and/or clinical investigation data. The TGA may accept a clinical evaluation report (CER) demonstrating equivalence to a device with established clinical performance. |
| Class IIb | Substantive clinical evaluation required. For higher-risk Class IIb devices (particularly implantables), clinical investigation data is often expected. Literature alone may be insufficient for novel technologies. |
| Class III | Robust clinical evidence required. Clinical investigation data is typically expected, particularly for novel devices or devices with a new intended purpose. Literature-based evaluation may be accepted for well-established technologies where equivalence to a device with extensive clinical data can be demonstrated. |
| AIMD | Same as Class III. Clinical investigation data is the norm. |
Clinical Evaluation Reports
The TGA expects a clinical evaluation report (CER) as part of the ARTG application for registered devices. The CER must:
- Define the device and its intended purpose
- Identify and appraise all relevant clinical data (from investigations, literature, and clinical experience)
- Analyze the clinical data to determine whether the device meets the Essential Principles for safety and performance
- Conclude on the benefit-risk balance
- Identify any residual risks and risk mitigation measures
- Describe the ongoing post-market clinical follow-up plan
The TGA generally accepts CERs prepared in accordance with MEDDEV 2.7/1 Rev. 4 (the EU guidance on clinical evaluation) or the IMDRF clinical evaluation guidance documents. Manufacturers who have prepared a CER for EU MDR compliance will find that the same document — with minor adaptation to reference Australian Essential Principles rather than EU GSPRs — can serve the Australian market.
Clinical Investigations in Australia
If you need to conduct a clinical investigation in Australia, you must:
- Obtain ethics approval — from a Human Research Ethics Committee (HREC) registered with the National Health and Medical Research Council (NHMRC)
- Notify the TGA — the TGA must be notified of clinical trials involving unapproved therapeutic goods. Depending on the device class, this may be a notification or require TGA approval before the trial begins
- Comply with Good Clinical Practice (GCP) — ISO 14155 (Clinical investigation of medical devices for human subjects — Good clinical practice) and the NHMRC National Statement on Ethical Conduct in Human Research
- Register the trial — clinical trials should be registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)
TGA Fees and Timelines
Understanding TGA fees is essential for budgeting your Australian market entry. The TGA's fee structure is set out in the Therapeutic Goods (Charges) Regulations and Schedule 5 of the Therapeutic Goods Regulations 1990. Fees are updated annually at the start of each financial year (1 July) and typically increase by 3–5% per year to reflect cost recovery indexation.
ARTG Application Fees (2025–2026 Financial Year)
These are the fees for submitting an application to include a medical device in the ARTG via the abbreviated (COR) pathway:
| Device Class | Application Fee (AUD) | Schedule 5 Reference |
|---|---|---|
| Class I (sterile, measuring function, or other — excluding export-only) | $621 | Items 1.5(e), 1.5(g) |
| Class IIa | $1,187 | Item 1.5(d) |
| Class IIb | $1,187 | Item 1.5(c) |
| Class III | $1,530 | Item 1.5(b) |
| AIMD | $1,530 | Item 1.5(b) |
| IVD (all classes requiring registration) | $1,187 | Item 1.5 |
Application Audit Assessment Fees
In addition to the application fee, the TGA may select an application for audit. For Class III and AIMD devices, a Level 2 audit is mandatory. For other classes, the TGA determines audit selection on a case-by-case basis using a risk-based framework.
| Audit Level | Assessment Fee (AUD) | Scope | Schedule 5 Reference |
|---|---|---|---|
| Level 1 | $4,700 | Verification of sponsor's application, evidence of conformity, and aspects of compliance against Essential Principles | Item 1.13 |
| Level 2 | $17,288 | Level 1 activities plus in-depth technical documentation review to determine compliance with Essential Principles — applies to Class III medical devices (excluding IVDs) | Item 1.14(a) |
Important: The Level 2 audit information must be provided within 20 working days of the TGA's request. Failure to provide the required documentation within this timeframe can result in the application being refused.
TGA Conformity Assessment Certificate Fees
If a manufacturer does not hold conformity assessment evidence from a recognized COR (such as CE marking, FDA clearance, or MDSAP certificate), they must obtain a TGA Conformity Assessment Certificate directly from the TGA. This is significantly more expensive and time-consuming than the abbreviated (COR) pathway:
| Device Class | TGA Conformity Assessment Fee (AUD) | Typical Timeline |
|---|---|---|
| Class II (IIa and IIb) | ~$34,999 | 6–12 months |
| Class III / AIMD | ~$100,849 | Up to 12+ months |
TGA Conformity Assessment Certificates must be renewed every five years. The renewal process involves a re-assessment of the manufacturer's quality management system and device documentation.
Cost comparison: For a Class III device, the abbreviated pathway costs approximately $1,530 (application fee) + $17,288 (Level 2 audit) = $18,818 AUD, compared to approximately $100,849 AUD for TGA conformity assessment. This represents an 80%+ cost saving — a compelling reason to secure CE marking, FDA clearance, or MDSAP certification before entering Australia.
Annual ARTG Charges
Every ARTG entry attracts an annual charge, payable on 1 July of each financial year. Annual charges apply to all entries that are active on the ARTG as of 1 July.
| Device Class | Annual Charge (AUD) |
|---|---|
| Class I (other — non-sterile, non-measuring) | $114 |
| Class I (sterile or measuring) | $828 |
| Class IIa | $1,230 |
| Class IIb | $1,230 |
| Class III | $1,566 |
| AIMD | $1,566 |
| IVD (all classes) | $893 |
Annual Charge Exemption (ACE) Scheme
Sponsors can apply for an exemption from annual charges for ARTG entries with zero turnover (i.e., devices that were not supplied in Australia during the financial year). Key dates for the ACE scheme:
| Date | Action |
|---|---|
| May–June | Update account details in TGA's Business Services portal (billing email, authorized users) |
| 13 June | Deadline to request voluntary revocation of manufacturing licences to avoid next year's charge |
| 30 June | Deadline to request voluntary ARTG cancellations; deadline to submit sponsor transfer requests; ARTG entries active on 1 July will incur annual charges unless exempt |
| 1 July | Annual fees and charges take effect for all active entries |
| 1–22 July | Submit online "$0 Turnover Declaration" for ACE exemption |
| 23 July – 15 September | Submit manual "Late Declaration" of $0 turnover (late fees apply) |
Practical tip for portfolio management: If you are no longer marketing certain devices in Australia, request voluntary ARTG cancellation before 30 June to avoid incurring annual charges for the next financial year. For devices you intend to market in the future but have not yet launched, file a $0 turnover declaration during the July window. This is a straightforward process but is frequently overlooked by sponsors, resulting in unnecessary annual charges.
Other Device-Related Fees
| Fee Type | Amount (AUD) |
|---|---|
| Device change request (up to 10 ARTG entries) | $360 |
| Sponsor transfer | Administrative fee applies; contact TGA for current amount |
| Export-only device listing | Reduced fee schedule applies |
Review Timelines
| Application Type | Typical Review Timeline | Notes |
|---|---|---|
| Class I listing (non-sterile, non-measuring) | Same day to 5 business days | Automatic inclusion upon sponsor self-certification |
| Class I listing (sterile or measuring) | 1–4 weeks | Requires conformity assessment evidence for sterile/measuring aspects |
| Class IIa (with COR evidence) | ~4 weeks | If no audit is triggered |
| Class IIb (with COR evidence) | ~6 weeks | If no audit is triggered |
| Class IIa–IIb (audit triggered) | 2–3 months | Audit selection extends timelines |
| Class III / AIMD (with COR evidence) | 3–6 months | Mandatory Level 2 audit included |
| Any class (TGA Conformity Assessment — no COR) | 6–12+ months | Full TGA assessment pathway |
| Standard application (no COR, all classes) | 150–255 calendar days | Legislative timeframe |
| Priority review | Reduced timelines (case-by-case) | Must meet eligibility criteria for serious/life-threatening condition |
These timelines are legislative timeframes — the TGA has target service standards, but actual timelines can exceed these targets during periods of high application volume or if the TGA issues requests for additional information. Each time the TGA requests additional information, the assessment clock stops and restarts when the sponsor provides a satisfactory response. Complex applications can take significantly longer than the standard timeframes.
Applications with conformity assessment evidence issued by the TGA or by an EU MDR Notified Body may be processed within one month. Applications with any other type of conformity assessment evidence may be selected for an application audit, which can add 4–12 months to the overall timeline.
Practical tip: The single biggest factor that extends TGA review timelines is incomplete applications and poor-quality documentation. Sponsors who submit complete, well-organized applications with all required evidence, a clear Essential Principles checklist, and a robust clinical evaluation report experience significantly shorter review times than those who submit incomplete or disorganized packages. Budget for a best case of the lower end of the timeline ranges and a realistic case of the upper end, plus 30–60 additional days for potential information requests.
IVD Registration in Australia
In vitro diagnostic devices (IVDs) are regulated under a separate but parallel framework within the Therapeutic Goods (Medical Devices) Regulations 2002.
IVD Classification
Australia classifies IVDs into four classes, aligned with the GHTF/IMDRF risk-based framework:
| IVD Class | Risk Level | Examples | ARTG Status |
|---|---|---|---|
| Class 1 IVD | Lowest | General lab reagents, specimen containers, buffer solutions, staining solutions, wash solutions | Listed |
| Class 2 IVD | Low–moderate | Clinical chemistry analyzers, hematology analyzers, self-testing devices (pregnancy, cholesterol), routine microbiology culture media | Registered |
| Class 3 IVD | Moderate–high | Companion diagnostics, blood glucose self-testing, HLA typing, tumor markers for screening, prenatal screening (Down syndrome) | Registered |
| Class 4 IVD | Highest | Blood grouping (ABO, Rh, Kell), HIV/HCV/HBV screening for blood donations, variant CJD testing | Registered |
IVD-Specific Requirements
- Analytical performance data — sensitivity, specificity, accuracy, precision, linearity, detection limits, and other performance characteristics must be validated
- Clinical performance data — clinical sensitivity and clinical specificity demonstrated through clinical performance studies using clinical specimens
- Australian reference population data — for certain IVDs, the TGA may require performance data relevant to the Australian population, particularly for diagnostics where population-specific reference ranges or disease prevalence affect performance
- Batch release testing — for Class 4 IVDs (blood screening tests), the TGA requires batch release testing of each production lot before it can be supplied in Australia
IVD Conformity Assessment
| IVD Class | Conformity Assessment | Conformity Assessment Body Required? |
|---|---|---|
| Class 1 | Manufacturer self-declaration | No |
| Class 2 | Full Quality Assurance (Parts 1 and 3) | Yes |
| Class 3 | Full Quality Assurance (Parts 1 and 3) + Design Examination (Part 6), or Type Examination + Product Verification | Yes |
| Class 4 | Full Quality Assurance (Parts 1 and 3) + Design Examination (Part 6) + Batch release testing | Yes |
IVD Reforms
The TGA has been progressively reforming its IVD regulatory framework to align more closely with the IVDR model and IMDRF guidance. Key developments include:
- Reclassification of IVDs: Many IVDs have been reclassified to higher classes under updated classification rules, similar to the IVDD-to-IVDR reclassification in Europe. Manufacturers whose IVDs were previously Class 1 (listed) may find they are now Class 2 or higher (requiring registration)
- Enhanced clinical evidence requirements: The TGA has strengthened expectations for clinical performance data, particularly for companion diagnostics, genetic tests, and self-testing devices
- Software IVDs: Software that performs an IVD function (e.g., algorithms that analyze clinical specimens or produce diagnostic results) is now explicitly regulated as an IVD device
Post-Market Requirements
ARTG inclusion is not the end of the regulatory journey — it is the beginning of ongoing post-market obligations that the sponsor must maintain for as long as the device is on the Australian market.
Adverse Event Reporting
The TGA operates a mandatory adverse event reporting system for medical devices. Sponsors must report:
| Report Type | Reporting Timeframe | Trigger |
|---|---|---|
| Serious threat to public health | Within 48 hours of becoming aware | Event that constitutes a serious threat to public health (e.g., widespread device failure affecting multiple patients) |
| Death or serious injury | Within 10 calendar days of becoming aware | Death or serious deterioration in health that the device may have caused or contributed to |
| Other reportable events | Within 30 calendar days of becoming aware | Events that did not result in death or serious injury but could lead to death or serious injury if they recurred |
| Near incidents | Within 30 calendar days of becoming aware | Near incidents that, if they had occurred, could have led to death or serious injury |
| Trend reports | As trends are identified | Statistically significant increase in the frequency or severity of non-serious incidents or expected side effects |
Reports are submitted through the TGA's electronic adverse event reporting system. The sponsor must investigate each adverse event, determine root cause, and implement corrective and preventive actions as appropriate.
Recalls and Field Safety Corrective Actions
When a medical device defect or safety issue is identified that requires corrective action, the sponsor must initiate a recall (known as a "field safety corrective action" in international terminology). The TGA classifies recalls by severity:
| Recall Classification | Description | Example |
|---|---|---|
| Class I | Use of, or exposure to, the product may cause death, be life-threatening, or cause a serious risk to health | Pacemaker with potential for sudden loss of output |
| Class II | Use of, or exposure to, the product may cause illness or mistreatment, but the situation is not Class I | Infusion pump with dosing inaccuracy outside specifications but not immediately life-threatening |
| Class III | Use of, or exposure to, the product is unlikely to cause illness or mistreatment, but the product does not meet legal requirements | Labeling errors that do not affect safe use; cosmetic defects |
The sponsor must notify the TGA of any recall action, provide a recall plan, execute the recall, and submit a close-out report. The TGA publishes recall information on its website, and sponsors are expected to communicate directly with affected healthcare facilities and users.
Post-Market Surveillance (PMS)
The TGA expects sponsors to maintain a systematic post-market surveillance system that includes:
- Complaint handling — systematic collection and analysis of complaints
- Adverse event monitoring — ongoing monitoring for adverse events from all sources (complaints, literature, registry data, overseas regulators)
- Periodic review — regular review of post-market data to identify trends, emerging risks, or opportunities for risk mitigation
- Literature monitoring — ongoing review of published literature relevant to the device
- Coordination with international vigilance — monitoring adverse event databases from other regulators (FDA MAUDE, EU vigilance, Health Canada) for signals relevant to the device
Ongoing ARTG Maintenance
Sponsors must:
- Pay annual charges — failure to pay annual charges results in cancellation of the ARTG entry
- Report changes — notify the TGA of changes to the device, manufacturing process, or sponsor details that could affect safety, performance, or classification
- Maintain conformity assessment evidence — keep conformity assessment certificates current (renewing MDSAP certificates, EU certificates, etc.)
- Update clinical evaluation — periodically update the clinical evaluation report to incorporate post-market clinical data
Trans-Tasman Mutual Recognition: Australia and New Zealand
The Trans-Tasman Arrangement
Australia and New Zealand have a long-standing mutual recognition arrangement for medical devices. Historically, this was governed by the Trans-Tasman Mutual Recognition Act 1997, which allowed devices registered with one country's regulator to be supplied in the other country without a separate registration process.
Under the current arrangement, devices included in the ARTG by the TGA are generally recognized by Medsafe (New Zealand's Medicines and Medical Devices Safety Authority). New Zealand maintains its own regulatory framework, but in practice, the two countries have worked toward regulatory alignment.
Current Status (2026)
The mutual recognition arrangement between Australia and New Zealand has evolved significantly:
- Medsafe accepts TGA registration as evidence of regulatory compliance for medical devices supplied in New Zealand. A device included in the ARTG can generally be supplied in New Zealand, subject to New Zealand's own notification and adverse event reporting requirements
- WAND database registration required: Even with ARTG inclusion, medical devices must be registered in Medsafe's Web-Assisted Notification of Devices (WAND) database within 30 working days of first being supplied in New Zealand. The WAND notification requires the manufacturer to declare that the device meets relevant standards and provide documentation including the ARTG number
- New Zealand's Therapeutic Products Act and Medical Products Bill — New Zealand has been developing comprehensive therapeutic products legislation. The Therapeutic Products Act received Royal Assent in 2023 and is being progressively implemented. In parallel, the Medical Products Bill is being developed to replace the Medicines Act 1981, with an expected commencement date around 2030. Once fully operational, this legislation will establish Medsafe as a standalone regulator with its own pre-market assessment requirements, though it is expected to maintain recognition of TGA assessments
- New Zealand's "Rule of Two" verification pathway: Under the Medicines Amendment Act 2025, New Zealand created an accelerated approval pathway for medicines (and potentially medical devices in future) that already hold full marketing authorization from at least two recognized regulatory authorities. This signals New Zealand's broader trend toward regulatory reliance, which may extend to medical devices as the Medical Products Bill progresses
- Memoranda of Understanding (MOUs): In September 2025, Singapore, Australia, and Ireland signed MOUs on medical device regulation, signaling deeper international cooperation. These MOUs are expected to facilitate information-sharing and streamline regulatory processes between the participating authorities
- For manufacturers targeting both markets, securing ARTG inclusion with the TGA is the most practical entry point, as it provides a pathway to both the Australian and New Zealand markets. The combined population of Australia (~26 million) and New Zealand (~5 million) represents a market of over 31 million with high healthcare expenditure
TTMRA Conditions and Limitations
While the Trans-Tasman Mutual Recognition Arrangement facilitates device supply between Australia and New Zealand, certain conditions must be met:
- The device must be lawfully supplied in the originating country (i.e., included in the ARTG for Australia, or meeting Medsafe requirements for New Zealand)
- Certain laws, including specific international obligations, are exempt from the TTMRA's application
- Each country maintains its own adverse event reporting requirements and recall procedures — the sponsor must comply with the reporting obligations of each country where the device is supplied
- The TGA requires progress reports on market actions at 6 weeks (interim) and 12 weeks (closeout), while Medsafe requires reports at 2 weeks (initial) and 6 weeks (follow-up)
Practical tip: While the Trans-Tasman arrangement makes New Zealand accessible via Australian registration, do not assume it is fully automatic. New Zealand has its own adverse event reporting requirements, WAND database notification obligations, and the evolving Medical Products Bill introduces changes that manufacturers need to track. Confirm the current recognition status with Medsafe before supplying devices in New Zealand based solely on your ARTG inclusion.
EU CE Marking Recognition in Australia
Historical Context
For many years, the TGA accepted EU CE marking as a primary form of conformity assessment evidence. This made Australia a relatively straightforward market for European manufacturers — a CE-marked device could enter Australia through the abbreviated pathway with minimal additional documentation.
Current Recognition Status (2026)
The TGA continues to accept CE marking as conformity assessment evidence, but with important updates reflecting the EU's transition from the MDD/IVDD directives to the MDR/IVDR regulations:
- MDD/AIMDD CE marking — still accepted for devices with valid legacy certificates that remain within the EU MDR transition provisions. However, as MDD certificates expire under the MDR transition deadlines (December 2027 for Class III/IIb implantable; December 2028 for others), the TGA will no longer accept these certificates for new ARTG applications
- MDR CE marking — accepted by the TGA. Devices with MDR CE certificates can use the abbreviated application pathway. The TGA recognizes MDR Notified Body certificates and technical documentation assessed under the MDR
- IVDR CE marking — accepted by the TGA for IVDs with valid IVDR certificates
- Important caveat: The TGA does not simply accept CE marking at face value. The abbreviated pathway still requires the sponsor to submit the CE certificate, Declaration of Conformity, summary of technical documentation, Essential Principles checklist (mapped to Australian requirements), clinical evaluation, and Australian-specific labeling information. The TGA reviews the application and can raise questions or request additional evidence
Impact of EU MDR Transition on Australian Applications
The EU MDR transition creates a time-limited complication for Australian applications. The key EU transition deadlines that directly affect TGA acceptance:
- 26 May 2026: Final deadline for Class III custom-made implantable devices to comply with MDR
- 31 December 2027: Final deadline for all other Class III devices and Class IIb implantable devices (with certain exceptions)
- 31 December 2028: Final deadline for remaining Class IIb, Class IIa, Class Is, and Class Im devices
| Scenario | TGA Acceptance |
|---|---|
| Valid MDD certificate (within EU transition deadlines) | Accepted for abbreviated pathway; new applications accepted while the MDD certificate remains valid under EU transitional provisions |
| MDD certificate expired or beyond EU transition deadline | No longer accepted; manufacturer must obtain MDR certification or use alternative conformity assessment evidence |
| Valid MDR certificate | Fully accepted for abbreviated pathway |
| Device lost CE marking (failed to transition to MDR) | Not accepted; manufacturer must use MDSAP, FDA clearance, or standard pathway for Australian application |
| MDD legacy device for UDI purposes | Extended transitional arrangements apply — e.g., MDD-certified Class III devices granted UDI labeling extension until January 2028 |
Strategic advice for EU manufacturers: If your device currently holds an MDD certificate and you have not yet completed MDR transition, be aware that your window for using MDD-based CE marking for new Australian ARTG applications is closing. The December 2027 and December 2028 EU deadlines will directly determine when the TGA stops accepting MDD certificates for new abbreviated pathway applications. Plan your Australian and European regulatory strategies together — MDR transition failure will affect not just your EU market access but also your ability to use the abbreviated pathway in Australia. Manufacturers who anticipate difficulty completing MDR transition should consider securing MDSAP certification or FDA clearance as alternative COR evidence for maintaining Australian market access.
Recent Reforms (2024–2026)
The TGA has been actively modernizing its medical device regulatory framework. Key reforms and developments include:
Regulatory Changes
- Strengthened post-market monitoring: The TGA has expanded its post-market surveillance capabilities, including enhanced data analytics, international information-sharing agreements with FDA, Health Canada, and EU Competent Authorities, and increased scrutiny of post-market data submitted by sponsors
- Mandatory hospital adverse event reporting (March 2026): From 21 March 2026, all public, private, and day hospitals in Australia are required to report injuries and suspected injuries related to medical devices to the TGA. This mandatory reporting requirement is being implemented in phases through March 2030, starting with death and serious injury reports for high-risk devices and expanding to cover near-misses and lower-risk devices over time
- SaMD regulatory framework maturation: The TGA has issued updated guidance on the regulation of software as a medical device, adopting the IMDRF SaMD framework and clarifying classification, clinical evidence, and change management requirements for software devices
- IVD regulatory reform: Progressive reclassification and strengthening of IVD requirements (as described in the IVD section above)
- Supply chain resilience: In response to global supply chain disruptions experienced during and after the COVID-19 pandemic, the TGA has introduced measures to improve visibility into device supply chains and to provide regulatory flexibility during shortages
- Expedited pathways refinement: The provisional registration and priority review pathways have been refined based on experience, with clearer eligibility criteria and more structured evidence requirements
- Alignment with IMDRF guidance: The TGA continues to align its regulatory practices with IMDRF guidance documents, reflecting Australia's active role in the IMDRF
- Expanded COR recognition: In October 2024, the TGA expanded reliance pathways for the US FDA, now accepting MDSAP Certification + FDA 510(k) clearance for Class III devices and MDSAP Certification + evidence of FDA exemption for Class IIa devices that are exempt from FDA 510(k) regulation
- Borderline products reclassification (January 2026): The Therapeutic Goods (Medical Devices—Specified Articles) Amendment Instrument 2025 added seven product types to the list of specified medical devices, while separately excluding four classes of boundary products (toothpastes, head/body lice treatments, moisturizers, and weight-loss treatments) from medical device regulation
- TGA Compliance Principles 2026–2027: The TGA published its compliance principles, outlining a proactive and risk-based enforcement approach for 2026 and 2027, with emphasis on AI/software devices, sponsor accountability, and post-market surveillance compliance
- Sponsor guidance clarification (January 2026): Updated guidance on importing and supplying medical devices, with clearer definitions of sponsor responsibilities, importation rules, and the circumstances under which health professionals are considered suppliers
Mandatory Hospital Adverse Event Reporting Timeline
| Phase | Period | Scope |
|---|---|---|
| Transition | March 2025 – March 2026 | IT system development; stakeholder training and education |
| Stage 1 | March 2026 – March 2028 | Reporting death and serious injury/deterioration related to high-risk medical devices |
| Stage 2 | March 2028 – March 2030 | Reporting death, serious injury/deterioration, and near misses for high- and medium-risk medical devices |
| Stage 3 | March 2030 onwards | Reporting death, serious injury/deterioration, and near misses for all medical devices |
Conformity Assessment Procedures (CAP) Reform
In December 2025, the TGA launched a major public consultation on proposed amendments to the conformity assessment procedures for medical devices. The consultation, extended to 14 April 2026, proposes eight reforms to the existing CAP framework that has been in place for over 20 years. The proposed changes are intended to:
- Improve clarity, efficiency, and alignment with international regulatory frameworks (including the EU MDR)
- Modernize the conformity assessment process for emerging technologies (software-based devices, AI, advanced manufacturing)
- Provide better monitoring of design and development methodologies
- Maintain the recognition of comparable overseas regulator approvals and assessments
Proposals 1–5 focus on the conformity assessment procedures for TGA conformity assessment certification (or future Australian conformity assessment bodies), while Proposals 6–8 also apply to devices certified by comparable overseas regulators. Manufacturers should monitor the outcome of this consultation as it will reshape the conformity assessment landscape in Australia.
Action required: If you are a medical device manufacturer or sponsor active in Australia, consider submitting feedback to the TGA consultation (devicereforms@tga.gov.au) before the 14 April 2026 deadline. This is a significant opportunity to influence the future regulatory framework.
Digital Health and AI/ML Devices
The TGA has been at the forefront of regulating AI/ML-based medical devices and digital health technologies:
- AI/ML action plan: The TGA published a regulatory framework for AI/ML-enabled medical devices, covering classification, pre-market assessment, and post-market monitoring of adaptive algorithms
- February 2026 AI guidance update: On 5 February 2026, the TGA updated two complementary guidance pages — "Artificial intelligence (AI) and medical device software regulation" and "Standards for software-based medical devices" — confirming that AI medical devices are regulated within the established SaMD framework rather than through a standalone AI-specific regime. The guidance reinforces that AI medical software must be supported by appropriate clinical evidence proportional to its risk classification and intended use, and that demonstrating technical performance alone is not sufficient
- AI-powered digital scribes and clinical tools: The TGA's 2025 compliance update specifically highlighted AI-powered digital scribes that suggest diagnoses or treatments as potentially falling within medical device regulation. Developers of such tools must assess whether their software meets the definition of a medical device and, if so, ensure ARTG inclusion
- Predetermined change control plans (PCCPs): Following the IMDRF framework, the TGA has signaled acceptance of predetermined change control plans for AI/ML devices, allowing certain algorithm updates to be implemented without a new ARTG application, provided the changes fall within pre-approved parameters
- Cybersecurity requirements: The TGA has published guidance on cybersecurity for medical devices, requiring manufacturers to address cybersecurity risks in their risk management process and to maintain ongoing cybersecurity monitoring as part of post-market surveillance
UDI Implementation — Australian UDI Database (AusUDID)
Australia's UDI regulatory framework came into legal effect on 24 March 2025 through an amendment to the Therapeutic Goods Regulations 2002. The Australian UDI Database (AusUDID) went live on the same date, and manufacturers can voluntarily comply during the initial phase (until 30 June 2026).
Medical Device UDI Compliance Start Dates
| Requirement | Class III | Class IIb | Class IIa | Class Is |
|---|---|---|---|---|
| Placing UDI carrier on device label | 1 July 2026 | 1 July 2026 | 1 July 2027 | 1 July 2028 |
| Submitting UDI-DIs and related data to AusUDID | 1 July 2026 | 1 July 2026 | 1 July 2027 | 1 July 2028 |
| Direct marking of device and submitting Direct Marking DI to AusUDID | 1 January 2028 | 1 January 2029* | Not yet specified | Not yet specified |
*Class IIb direct marking deadline of 1 January 2029 is not applicable for implantable medical devices. Other Class I medical devices (non-sterile, non-measuring) have voluntary UDI compliance.
IVD UDI Compliance Start Dates
IVD devices have a separate phased compliance schedule, with higher-risk IVD classes (Class 4, Class 3) required to comply first.
Transitional Dates for EU MDD Legacy Devices
The TGA provides extended transitional arrangements for devices still supplied under legacy European MDD certificates. For example, MDD-certified Class III devices are granted an extension until January 2028 for UDI labeling and data submission.
The UDI system will provide a public database of UDI information, enabling patients to find details about their medical devices. Healthcare organizations can integrate UDI information with their systems and patient records, including the government's My Health Record system. The full implementation period for UDI compliance runs through to 30 June 2030.
Immediate action required: If you supply Class III or Class IIb medical devices in Australia, you must be compliant with UDI labeling and AusUDID data submission by 1 July 2026. This requires changes to labeling, packaging artwork, and data management systems that should be initiated now if not already underway.
Other Upcoming Changes
Manufacturers entering the Australian market should monitor several additional developments expected through 2026 and beyond:
- Essential Principles revision — further alignment with EU MDR GSPRs and IMDRF guidance; the TGA has reviewed consultation submissions and is preparing updated requirements
- Electronic labeling (e-IFU) — the TGA is considering expanded acceptance of electronic instructions for use, aligned with international trends
- In-house IVD arrangements — the TGA is reviewing the regulatory framework for IVDs manufactured and used within the same healthcare institution
- Patient-matched medical devices (PMMD) — proposed refinements to the current regulatory arrangements for personalized medical devices, including those manufactured at the point of care
- Clinical Decision Support System (CDSS) exemption — the Australian Government has agreed to prepare regulatory amendments refining the exemption requirements for CDSS that are not classified as medical devices
- Surgical loan kits (SLKs) — the TGA is finalizing and publishing guidance on the regulation of surgical loan kits
- Regulatory convergence initiatives — continued participation in IMDRF and bilateral regulatory cooperation agreements (including discussions with UK MHRA and Brazil ANVISA), which may further streamline market access for devices already approved in recognized jurisdictions
Australia vs. EU vs. FDA: A Comparison
Understanding how the TGA compares to other major regulators helps manufacturers plan multi-market regulatory strategies.
| Dimension | Australia (TGA) | European Union (MDR/IVDR) | United States (FDA) |
|---|---|---|---|
| Governing law | Therapeutic Goods Act 1989; Medical Devices Regulations 2002 | Regulation (EU) 2017/745 (MDR); Regulation (EU) 2017/746 (IVDR) | Federal Food, Drug, and Cosmetic Act; 21 CFR Parts 800–1299 |
| Regulatory authority | TGA (single national authority) | 27 Competent Authorities + Notified Bodies + European Commission | FDA (single federal authority) |
| Device register | ARTG (publicly searchable; AUST L/AUST R numbers) + AusUDID (from July 2026) | EUDAMED (mandatory modules phasing in from May 2026) | FDA device registration database; 510(k)/PMA/De Novo databases; GUDID (UDI) |
| Classification | Class I, IIa, IIb, III, AIMD (GHTF-aligned) | Class I, IIa, IIb, III (22 rules) | Class I, II, III (product code-based) |
| IVD classification | Class 1–4 (risk-based) | Class A–D (risk-based, 7 rules) | Class I, II, III (product code-based) |
| Conformity assessment | Essential Principles checklist; accepts MDSAP, CE marking, FDA clearance | GSPR checklist; Notified Body assessment (except Class I) | Substantial equivalence (510(k)); reasonable assurance (De Novo/PMA) |
| Local representative required | Yes — Australian sponsor mandatory | Yes — Authorized Representative for non-EU manufacturers | Yes — US Agent for foreign establishments; US correspondent |
| Clinical evidence | CER expected; follows IMDRF/MEDDEV guidance | CER mandatory (Annex XIV); PMCF required | Clinical data requirements vary by pathway; IDE for investigations |
| QMS standard | ISO 13485 (via MDSAP or EU NB certificate) | ISO 13485 (audited by Notified Body) | 21 CFR Part 820 (QMSR, transitioning to ISO 13485 alignment) |
| MDSAP accepted | Yes — as conformity assessment evidence | No — EU is not an MDSAP participant | Yes — as substitute for routine FDA inspections |
| Post-market surveillance | Mandatory adverse event reporting; recalls; PMS | Mandatory PMS plan, PSUR/PMS report, PMCF, vigilance | MDR (21 CFR Part 803); recalls; annual/periodic reports for PMA |
| Typical review timeline (Class III) | 150–255 calendar days (standard) | 13–18 months (Notified Body assessment) | ~12–18 months (PMA); ~108–142 days (510(k) for equivalent risk) |
| Mutual recognition | Trans-Tasman (New Zealand); abbreviated pathway for EU/FDA/HC | Recognized in 27 EU/EEA member states; accepted by TGA, others | Bilateral agreements with some countries; not directly recognized by EU for market access |
Key takeaway: For manufacturers planning a global regulatory strategy, Australia sits in a unique position as a jurisdiction that actively leverages international regulatory work. The TGA's acceptance of MDSAP, CE marking, and FDA clearances means that the incremental effort to enter Australia — when you already have one or more major-market clearances — is relatively modest compared to markets like China, Japan, or Brazil that have more standalone regulatory processes.
Tips for Foreign Manufacturers
Based on the practical realities of navigating the Australian regulatory landscape, here is guidance for foreign manufacturers planning to enter the Australian market.
1. Secure Your Australian Sponsor Early
This is the single most critical step. Without an Australian sponsor, you cannot apply for ARTG inclusion. Begin identifying and engaging your sponsor — whether a distributor, a regulatory agent, or your own Australian subsidiary — well before you plan to submit your ARTG application.
2. Leverage Existing International Certifications
If you already hold CE marking, FDA clearance, or an MDSAP certificate, use the abbreviated pathway. The time and cost savings are substantial compared to the standard pathway. Ensure your existing certification documentation is complete and well-organized before submission.
3. Prepare Australia-Specific Labeling Early
Australian labeling requirements include sponsor name and address on the label, AUST R or AUST L number (assigned upon ARTG inclusion), and compliance with TGA labeling guidance. Plan your labeling artwork changes in parallel with your ARTG application — do not wait until after approval to discover you need label changes that require production line modifications.
4. Map Your Essential Principles Checklist
Even if you have a GSPR checklist for EU MDR or a performance standards checklist for FDA, you need an Essential Principles checklist specific to the Australian regulations. The overlap is significant, but not 100%. Dedicate time to mapping your existing compliance documentation to the Australian Essential Principles.
5. Budget for Annual ARTG Charges
Unlike some other jurisdictions where registration is a one-time cost, the ARTG requires annual charges per entry. For manufacturers with large portfolios, annual charges can be tens of thousands of Australian dollars. Factor this into your market entry business case.
6. Understand the ARTG Entry Structure
The ARTG uses a "kind of device" structure. A single ARTG entry can cover a family of device variants if they share the same intended purpose, classification, and essential technology. Careful ARTG entry structuring can reduce the number of entries (and therefore annual charges) required. Work with your regulatory advisor to optimize your ARTG entry strategy.
7. Maintain Your Conformity Assessment Evidence
If your ARTG entry relies on a CE certificate, MDSAP certificate, or other international certification, ensure that certificate remains valid for as long as you want to maintain your ARTG entry. Certificate expiry without renewal can trigger TGA review of your ARTG entry status.
8. Plan for Post-Market Obligations From Day One
Do not treat post-market surveillance and adverse event reporting as afterthoughts. Establish your Australian adverse event reporting processes before you start supplying devices. Ensure your complaint handling system can identify and escalate TGA-reportable events within the required timeframes (48 hours for serious public health threats, 10 days for death or serious injury).
9. Monitor TGA Regulatory Updates
The TGA publishes regulatory updates, guidance documents, and consultation papers on its website (tga.gov.au). Subscribe to TGA email alerts and monitor the TGA's consultation hub for proposed changes that could affect your devices. The regulatory environment in Australia is actively evolving, and changes can affect classification, clinical evidence requirements, or labeling obligations.
10. Consider the Trans-Tasman Opportunity
When entering the Australian market, simultaneously explore the New Zealand market. The Trans-Tasman arrangement means your ARTG inclusion may provide a pathway to New Zealand, effectively giving you access to two markets through a single regulatory process. Confirm the current mutual recognition provisions with Medsafe.
11. Use Pre-Submission Meetings
The TGA offers pre-submission meetings where manufacturers and sponsors can discuss regulatory strategy, classification questions, clinical evidence requirements, and application approach before submitting the formal application. These meetings are particularly valuable for novel devices, devices with ambiguous classification, or devices where the clinical evidence strategy requires TGA alignment.
12. Engage Experienced Local Expertise
The Australian regulatory landscape has nuances that are not obvious from reading the legislation alone. Engage an experienced Australian regulatory affairs professional — whether in-house, through your sponsor, or through a consulting firm — who understands TGA processes, common deficiencies, and current assessment priorities. The investment in quality regulatory support pays for itself through faster review times, fewer information requests, and reduced risk of rejection.
Conclusion
Australia's TGA operates a sophisticated, risk-proportionate regulatory framework that is well-aligned with international standards while maintaining its own distinct requirements. For foreign manufacturers, the key to efficient market entry is understanding the sponsor requirement, leveraging existing international certifications through the abbreviated pathway, and treating post-market obligations with the same seriousness as pre-market registration.
The TGA's participation in MDSAP, its recognition of CE marking and FDA clearances, and the Trans-Tasman arrangement with New Zealand make Australia one of the more accessible major markets for manufacturers who already have regulatory approvals in other recognized jurisdictions. But accessibility does not mean automatic — thorough preparation, complete documentation, and a competent Australian sponsor are essential.
As the TGA continues to modernize its framework through 2026 and beyond — with reforms to Essential Principles, IVD classification, AI/ML device regulation, and UDI implementation — manufacturers who establish a strong regulatory foundation now will be well-positioned to maintain and expand their Australian market presence as requirements evolve.